ALB and neoplasm: Next, the tumor targeting potential of C/M@Alb NCs was evaluated by measuring the distribution of MTX from C/M@Alb NCs to the tumor and major organs (liver, heart, lungs, spleen, and kidney) after 24 h of single injection at an MTX dose of 10.0 mg kg−1.